Skip to content

IIT Clinical Trial Study on Cavity Tumor Disaggregation Therapy

IIT Clinical Trial Study on Cavity Tumor Disaggregation Therapy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124179
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cavity Tumors

Interventions

Experimental group:Perfusion LDH/EDTA

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.CT and MRI Scoring, Auxiliary Examination Diagnosis, and Pathological Diagnosis Confirm Cavity Tumors, Including: Non-Muscle-Invasive Bladder Cancer and Colorectal Cancer; 2.Age >= 18 years; 3.The cavity tumor is clearly diagnosed, and conventional treatments are ineffective or intolerable; 4.No severe dysfunction of vital organs such as the heart, liver, or kidneys; 5.Patients with bladder cancer must have non-muscle-invasive bladder cancer and either refuse or are unable to tolerate BCG instillation or radical cystectomy; 6.Patients must demonstrate good compliance and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with severe comorbidities such as malnutrition, cachexia, ascites, or other terminal-stage tumor conditions. 2.Patients with underlying hematologic disorders such as coagulation factor abnormalities. 3.Patients with existing perforation or a significant risk of potential perforation. 4.Pregnant or lactating women. 5.Patients with concurrent multi-organ tumors, severe uncontrolled medical conditions, or acute infections. 6.Any medical history that, in the judgment of the investigator, may interfere with the trial results or increase patient risk. 7.Patients who are unable to comprehend the study objectives or do not agree to the study requirements. 8.Individuals lacking legal capacity or with restricted legal capacity. 9.The investigator determines that the patient has poor compliance and is unable to cooperate with sample collection.

Design outcomes

Primary

MeasureTime frame
Tumor volume and recurrence-free rate;

Secondary

MeasureTime frame
Urinary methylation assay value;Carcinoembryonic antigen (CEA) level;Complete organ preservation rate;

Countries

China

Contacts

Public ContactYang Yan

Shanghai Tenth People's Hospital

13564368328@163.com+86 21 66301604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026